Search for a trial

An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma

Primary Objectives- To evaluate the pharmacokinetics and safety of the Dara-MD SC delivery of daratumumab (Part 1).- To evaluate the pharmacokinetics and safety of the Dara-CF SC delivery of daratumumab (Part 2).-To evaluate the safety of Dara-CF…

A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma

Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

This study has been transitioned to CTIS with ID 2023-503467-41-00 check the CTIS register for the current data. The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and…

An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or
Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular
Lymphoma

The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL). Another purpose of the study is to see if…

A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

Primary Objective- To evaluate if daratumumab can effectively decrease M protein in subjects with intermediate or high-risk SMM as assessed by CR rate- To determine if daratumumab reduces the progression/death rate in subjects with intermediate or…

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy

This study has been transitioned to CTIS with ID 2023-506125-10-00 check the CTIS register for the current data. The primary objective is to determine if the addition of daratumumab to VRd will prolong PFS defined as the time from the date of…

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-503620-60-00 check the CTIS register for the current data. The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination…

Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

This study has been transitioned to CTIS with ID 2024-510800-35-00 check the CTIS register for the current data. Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and…

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC
and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and
Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in
Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended
for Autologous Stem Cell Transplant as Initial Therapy

This study has been transitioned to CTIS with ID 2023-503442-30-00 check the CTIS register for the current data. The purpose of this study is to compare the efficacy of teclistamab and talquetamab both in combination with daratumumab and…